Skip navigation
Universidade Federal da Bahia |
Repositório Institucional da UFBA
Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/43159
Registro completo de metadados
Campo DCValorIdioma
dc.creatorMüller, Gabriel Saldanha-
dc.date.accessioned2025-10-08T12:20:12Z-
dc.date.available2025-10-08T12:20:12Z-
dc.date.issued11-07-
dc.identifier.citationMÜLLER, Gabriel Saldanha. Descrição do perfil imunofenotípico de indivíduos com leucemia mieloide aguda associado a mutações em NPM1 e FLT3-ITD em população da Bahia. 2025. Dissertação (Mestrado). Programa de Pós-Graduação em Imunologia, Universidade Federal da Bahia, Salvador, 2025.pt_BR
dc.identifier.urihttps://repositorio.ufba.br/handle/ri/43159-
dc.description.abstractAcute myeloid leukemia (AML) is caused by the clonal proliferation of precursor cells of the myeloid lineage. The diagnosis of AML is made by identifying clinical and laboratory signs, including the percentage of leukemic blasts in peripheral blood or bone marrow, immunophenotyping, and molecular alterations. It is described in the literature that genetic alterations associated with AML may influence prognosis, cellularity, and the expression of cellular markers on blasts in different populations. The objective of this study was to analyze, in the treated population, the cellularity, cellular markers in myeloblasts, and mutations in the NPM1 and FLT3 (ITD) genes in patients with AML in Bahia. Peripheral blood and bone marrow were collected from 114 individuals with de novo AML, non-APL subtype, without prior chemotherapy, confirmed by immunophenotyping between 2019 and 2025. The study participants were classified according to sex and NPM1 and FLT3-ITD mutational status. Cellularity and the presence of cellular markers in myeloblasts (CD2, memCD3, citCD3, CD7, CD10, CD11b, CD13, CD14, CD15, CD16, CD19, CD33, CD34, CD35, CD38, CD45, CD56, CD64, CD71, CD79a, CD117, CD123, CD300e, HLA-DR, MPO) were analyzed by flow cytometry. This study identified that the profile of this study population shows a lower average age, a higher predominance of females, and a lower frequency of NPM1 and FLT3-ITD mutations compared to those described in other studies. The population had high 90-day mortality, with a marked effect of NPM1 and FLT3-ITD co-mutation, different from what is described in the literature for this mutation status. There is an association of lower frequency of the CD34 and HLA-DR markers in individuals with NPM1 mutation and higher frequency of CD2, CD7, and CD11b in individuals with FLT3-ITD mutation. The analysis of overall survival and immunophenotyping demonstrates parameters that are not commonly described in the literature and may be associated with the profile of this population.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal da Bahiapt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectLeucemia mieloide agudapt_BR
dc.subjectPrognósticopt_BR
dc.subjectImunofenotipagempt_BR
dc.subjectNPM1pt_BR
dc.subjectFLT3-ITDpt_BR
dc.subject.otherAcute myeloid leukemiapt_BR
dc.subject.otherPrognosispt_BR
dc.subject.otherImmunophenotypingpt_BR
dc.subject.otherNPM1pt_BR
dc.subject.otherFLT3-ITDpt_BR
dc.titleDescrição do Perfil Imunofenotípico de Indivíduos com Leucemia Mieloide Aguda Associado a Mutações em NPM1 e FLT3-ITD em População da Bahiapt_BR
dc.title.alternativeDescription of the Immunophenotypic Profile of Individuals with Acute Myeloid Leukemia Associated with Mutations in NPM1 and FLT3-ITD in a Population of Bahiapt_BR
dc.typeDissertaçãopt_BR
dc.publisher.programPrograma de Pós-Graduação em Imunologia - (PPGIM) pt_BR
dc.publisher.initialsUFBApt_BR
dc.publisher.countryBrasilpt_BR
dc.subject.cnpqCNPQ::CIENCIAS BIOLOGICAS::GENETICApt_BR
dc.subject.cnpqCNPQ::CIENCIAS BIOLOGICAS::IMUNOLOGIApt_BR
dc.contributor.advisor1Freire, Songeli Menezes-
dc.contributor.advisor1IDhttps://orcid.org/0000-0001-6547-6884pt_BR
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/8634866589762862pt_BR
dc.contributor.advisor-co1Lopes, Bruno de Almeida-
dc.contributor.advisor-co1IDhttps://orcid.org/0000-0003-1072-470Xpt_BR
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/0247465435713847pt_BR
dc.contributor.referee1Freire, Songeli Menezes-
dc.contributor.referee1IDhttps://orcid.org/0000-0001-6547-6884pt_BR
dc.contributor.referee1Latteshttp://lattes.cnpq.br/8634866589762862pt_BR
dc.contributor.referee2Lopes, Bruno de Almeida-
dc.contributor.referee2IDhttps://orcid.org/0000-0003-1072-470Xpt_BR
dc.contributor.referee2Latteshttp://lattes.cnpq.br/0247465435713847pt_BR
dc.contributor.referee3Silva Neto, Marinho Marques da-
dc.contributor.referee3IDhttps://orcid.org/0000-0002-9728-7268pt_BR
dc.contributor.referee3Latteshttp://lattes.cnpq.br/5902997490005100pt_BR
dc.contributor.referee4Pina, Eugênia Terra Granado-
dc.contributor.referee4IDhttps://orcid.org/0000-0002-3616-140Xpt_BR
dc.contributor.referee4Latteshttp://lattes.cnpq.br/7195311051600948pt_BR
dc.creator.IDhttps://orcid.org/0000-0002-5485-8059pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/5546176725335115pt_BR
dc.description.resumoLeucemia mieloide aguda (LMA) é causada por proliferação clonal de células precursoras da linhagem mieloide. O diagnóstico de LMA é realizado pela identificação de sinais clínicos e laboratoriais, incluindo porcentagem de blastos leucêmicos no sangue periférico ou medula óssea, imunofenotipagem e alterações moleculares. É descrito na literatura que alterações genéticas associadas à LMA podem influenciar no prognóstico, na celularidade e na expressão de marcadores celulares em blastos em diferentes populações. O objetivo deste estudo foi analisar na população atendida a celularidade, os marcadores celulares em mieloblastos e as mutações nos genes NPM1 e FLT3 (ITD) em pacientes com LMA na Bahia. Foi coletado sangue periférico e medula óssea de 114 indivíduos com LMA de novo, subtipo não-LPA, sem quimioterapia prévia, confirmados por imunofenotipagem entre 2019 e 2025. Os participantes do estudo foram classificados de acordo com o sexo e status mutacional NPM1 e FLT3-ITD. Foi analisada a celularidade e a presença de marcadores celulares em mieloblastos (CD2, memCD3, citCD3, CD7, CD10, CD11b, CD13, CD14, CD15, CD16, CD19, CD33, CD34, CD35, CD38, CD45, CD56, CD64, CD71, CD79a, CD117, CD123, CD300e, HLA-DR, MPO) por citometria de fluxo. Este estudo identificou que o perfil desta população de estudo possui menor idade média, maior predominância do sexo feminino, menor frequência de mutação em NPM1 e FLT3-ITD, em comparação com os descritos em outros estudos. A população teve alta mortalidade em 90 dias, com efeito marcante da comutação NPM1 e FLT3-ITD, diferente do descrito na literatura para este status de mutação. Há associação da menor frequência dos marcadores CD34 e HLA-DR em indivíduos com mutação em NPM1 e maior frequência de CD2, CD7 e CD11b em indivíduos com mutação FLT3-ITD. A análise da sobrevivência global e imunofenotipagem demonstra parâmetros que não são comumente descritos na literatura e podem estar associados ao perfil desta população.pt_BR
dc.publisher.departmentInstituto de Ciências da Saúde - ICSpt_BR
dc.relation.referencesANGELINI, Daniela F. et al. A leukemia-associated CD34/CD123/CD25/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clinical Cancer Research, v. 21, n. 17, p. 3977-3985, 2015. BALANDRÁN, Juan Carlos; LASRY, Audrey; AIFANTIS, Iannis. The role of inflammation in the initiation and progression of myeloid neoplasms. Blood Cancer Discovery, v. 4, n. 4, p. 254-266, 2023. BAQAI, Junaid; CRISAN, Domnita. Correlation of FLT3 mutations with expression of CD7 in acute myeloid leukemia. Applied Immunohistochemistry & Molecular Morphology, v. 23, n. 2, p. 104-108, 2015. BARON, Frédéric et al. Graft‐versus‐host disease and graft‐versus‐leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. British journal of haematology, v. 188, n. 3, p. 428-437, 2020. BENNETT, John M. et al. Is the association of “cup-like” nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful?. American journal of clinical pathology, v. 134, n. 4, p. 648-652, 2010. BISPO, Jordan A. Baeker; PINHEIRO, Paulo S.; KOBETZ, Erin K. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harbor perspectives in medicine, v. 10, n. 6, p. a034819, 2020. BRAY, Freddie et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, v. 68, n. 6, p. 394-424, 2018. CAO, Xuanqi et al. CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia. Experimental Hematology & Oncology, v. 11, n. 1, p. 67, 2022. CHAN, Onyee et al. The prognostic impact of FLT3 in NPM1-mutated AML: Co-occurrence of FLT3-ITD and FLT3-TKD confers poor outcomes. Blood, v. 140, n. Supplement 1, p. 3435-3437, 2022. CHAUHAN, Pradeep Singh et al. Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. Disease markers, v. 35, n. 5, p. 581-588, 2013. CHEN, Xueyan; CHERIAN, Sindhu. Acute myeloid leukemia immunophenotyping by flow cytometric analysis. Clinics in laboratory medicine, v. 37, n. 4, p. 753-769, 2017. DALAL, Bakul I. et al. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Clinical Lymphoma Myeloma and Leukemia, v. 12, n. 4, p. 274-279, 2012. DE LIMA, Marcos et al. AML and the art of remission maintenance. Blood Reviews, v. 49, p. 100829, 2021. DESCHLER, Barbara; LÜBBERT, Michael. Acute myeloid leukemia: epidemiology and etiology. Cancer: Interdisciplinary International Journal of the American Cancer Society, v. 107, n. 9, p. 2099-2107, 2006. DINARDO, Courtney D. et al. Acute myeloid leukaemia. The Lancet, v. 401, n. 10393, p. 2073-2086, 2023. DÖHNER, Hartmut et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, The Journal of the American Society of Hematology, v. 140, n. 12, p. 1345-1377, 2022. DÖHNER, Hartmut et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, The Journal of the American Society of Hematology, v. 129, n. 4, p. 424-447, 2017. DÖHNER, Konstanze et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, v. 106, n. 12, p. 3740-3746, 2005. DONG, Ying et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Experimental hematology & oncology, v. 9, p. 1-11, 2020. FALINI, Brunangelo et al. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood, The Journal of the American Society of Hematology, v. 136, n. 15, p.1707-1721, 2020. FORGHIERI, Fabio et al. NPM1-mutated myeloid neoplasms with< 20% blasts: a really distinct clinico-pathologic entity?. International Journal of Molecular Sciences, v. 21, n. 23, p. 8975, 2020. FORSYTHE, Anna; SANDMAN, Karen. What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations. Journal of Blood Medicine, p. 245-255, 2021. GAJENDRA, Smeeta et al. CD34 negative HLA‐DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3‐ITD mutations. International Journal of Laboratory Hematology, v. 45, n. 2, p. 221-228, 2023. GARCIAZ, Sylvain et al. Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available. Leukemia & Lymphoma, v. 65, n. 5, p. 700-703, 2024. GOEL, Harsh et al. Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. American journal of blood research, v. 11, n. 5, p. 472, 2021. GRIMWADE, David; HILLS, Robert K. Independent prognostic factors for AML outcome. ASH Education Program Book, v. 2009, n. 1, p. 385-395, 2009. HAFERLACH, Torsten et al. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. Leukemia research, v. 36, n. 1, p. 51-58, 2012. HESHMAT-GHAHDARIJANI, Kian et al. The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers: a narrative review. Frontiers in Oncology, v. 13, p. 1228076, 2023. INCA. Estimativas 2023: Incidência de Câncer no Brasil. Instituto Nacional de Câncer. Rio de Janeiro, 2022. JENTZSCH, Madlen et al. Clinical implications of the FLT3-ITD allelic ratio in acute myeloid leukemia in the context of an allogeneic stem cell transplantation. Cancers, v. 15, n. 4, p. 1312, 2023. JIMENEZ-MORALES, Silvia et al. Understanding leukemia biology using genome editing techniques. Frontiers in Oncology, v. 13, p. 1323584, 2023. JULIUSSON, Gunnar et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, The Journal of the American Society of Hematology, v. 113, n. 18, p. 4179-4187, 2009. JULIUSSON, Gunnar et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood advances, v. 4, n. 6, p. 1094-1101, 2020. KAMPEN, Kim R. The discovery and early understanding of leukemia. Leukemia research, v. 36, n. 1, p. 6-13, 2012. KAZI, Julhash U.; RÖNNSTRAND, Lars. FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications. Physiological reviews, v. 99, n. 3, p. 1433-1466, 2019. KHALDOYANIDI, Sophia et al. Immune biology of acute myeloid leukemia: implications for immunotherapy. Journal of Clinical Oncology, v. 39, n. 5, p. 419, 2021. KHOURY, Joseph D. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia, v. 36, n. 7, p. 1703-1719, 2022. KURZER, Jason H.; WEINBERG, Olga K. Atualizações em genética molecular da leucemia mieloide aguda. In: Seminários em Patologia Diagnóstica . WB Saunders, 2023. LEIFHEIT, Malia E. et al. Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia. International Journal of Molecular Sciences, v. 25, n. 17, p. 9448, 2024. LEWIS, Robert E. et al. Aberrant expression of T-cell markers in acute myeloid leukemia. Experimental and molecular pathology, v. 83, n. 3, p. 462-463, 2007. LI, Shuping et al. FLT3-TKD in the prognosis of patients with acute myeloid leukemia: a meta-analysis. Frontiers in Oncology, v. 13, p. 1086846, 2023. LIU, Song-Bai et al. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. Haematologica, v. 104, n. 1, p. e9, 2019. LIU, Yan-Rong et al. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. Leukemia research, v. 37, n. 7, p. 737-741, 2013. MARANI, L. O. et al. A expressão diferencial de células progenitoras leucêmicas definidas por CD99/CD123 está associada à mutação FLT3-ITD e recaída na leucemia mieloide aguda. Hematology, Transfusion and Cell Therapy, v. 44, p. S153-S154, 2022. MARSHALL, R. C. et al. Lower frequency of NPM 1 and FLT 3‐ITD mutations in a South African adult de novo AML cohort. International journal of laboratory hematology, v. 36, n. 6, p. 656-664, 2014. MASON, Emily F. et al. A distinct immunophenotype identifies a subset of NPM1‐mutated AML with TET2 or IDH1/2 mutations and improved outcome. American journal of hematology, v. 93, n. 4, p. 504-510, 2018. MELO, Carolina Pereira Souza et al. Correlation between FLT3–ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias. Leukemia Research, v. 39, n. 2, p. 131-137, 2015. MILMAN, Tatyana et al. The 5th edition of the World Health Organization Classification of Tumours of the Eye and Orbit. Ocular oncology and pathology, v. 9, n. 3-4, p. 71-95, 2023. MOASSASS, Faten et al. The Clinical Impact of NPM1 Mutations and the Effect of Concurrent Mutations in Acute Myeloid Leukemia: Unraveling the Prognostic Significance. Health Science Reports, v. 7, n. 12, p. e70231, 2024. MUÑOZ, Luz et al. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. haematologica, v. 88, n. 6, p. 637-645, 2003. MURPHY, Tracy; YEE, Karen WL. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert opinion on pharmacotherapy, v. 18, n. 16, p. 1765-1780, 2017. MUSHTAQ, Muhammad Umair et al. Prognostic significance of neutrophil-to-lymphocyte ratio in relapsed/refractory acute myeloid leukemia. Blood, v. 132, p. 5246, 2018. NABHAN, Chadi; KAMAT, Siddhesh; KARL KISH, Jonathan. Acute myeloid leukemia in the elderly: what constitutes treatment value?. Leukemia & Lymphoma, v. 60, n. 5, p. 1164-1170, 2019. NAJI, Nour Sabiha; SATHISH, Mrudula; KARANTANOS, Theodoros. Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia. Cancers, v. 16, n. 23, p. 3974, 2024. NAEIM, Faramarz et al. Principles of immunophenotyping. Atlas of hematopathology, p. 29-56, 2018. NOGUERA, N. I. et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia, v. 19, n. 8, p. 1479-1482, 2005. NOLLMANN, Cathrin et al. Characterization of CD34+ Cells from Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Using a t-Distributed Stochastic Neighbor Embedding (t-SNE) Protocol. Cancers, v. 16, n. 7, p. 1320, 2024. OBSERVATÓRIO DE ONCOLOGIA. Tendências da Mortalidade por leucemia no Brasil. 2020. Disponível em: https://public.tableau.com/app/profile/nelson.francisco.correa.netto5809/viz/shared/SC7F84DN7. Acesso em: 15 Jan. 2025. ORFAO, Alberto et al. Immunophenotypic dissection of normal hematopoiesis. Journal of Immunological Methods, v. 475, p. 112684, 2019. PADMAKUMAR, Devipriya et al. A concise review on the molecular genetics of acute myeloid leukemia. Leukemia Research, v. 111, p. 106727, 2021. PALMEIRA, Nathalia Campos et al. Análise do acesso a serviços de saúde no Brasil segundo perfil sociodemográfico: Pesquisa Nacional de Saúde, 2019. Epidemiologia e serviços de saúde, v. 31, p. e2022966, 2022. PAPADOPOULOU, Vasiliki et al. Characteristics and Prognosis of “Acute Promyelocytic Leukemia-like” Nucleophosmin-1-Mutated Acute Myeloid Leukemia in a Retrospective Patient Cohort. Biomedicines, v. 12, n. 10, p. 2282, 2024. PARK, Yumi et al. The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia. Blood research, v. 53, n. 3, p. 198, 2018. PARK, Sang Hyuk et al. Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals. Journal of Hematopathology, v. 16, n. 2, p. 73-84, 2023. PASSEGUÉ, Emmanuelle et al. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proceedings of the National Academy of Sciences, v. 100, n. suppl_1, p. 11842-11849, 2003. PESSOA, Flávia Melo Cunha de Pinho et al. Association between immunophenotypic parameters and molecular alterations in acute myeloid leukemia. Biomedicines, v. 11, n. 4, p. 1098, 2023. PITEL, Beth A. et al. Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia. Blood cancer journal, v. 13, n. 1, p. 138, 2023. PORTUGAL, Rodrigo Doyle; NUCCI, Márcio Luiz Moore. Current treatment preferences in acute myeloid leukemia: a survey in Brazil. Hematology, transfusion and cell therapy, v. 42, n. 3, p. 252-254, 2020. POSCH, P. E.; HURLEY, C. K. Histocompatibility: HLA and other systems. In: Blood and Bone Marrow Pathology. Churchill Livingstone, 2011. p. 641-676. RADU, Petru et al. CD34—Structure, functions and relationship with cancer stem cells. Medicina, v. 59, n. 5, p. 938, 2023. RANIERI, Roberta et al. Current status and future perspectives in targeted therapy of NPM1-mutated AML. Leukemia, v. 36, n. 10, p. 2351-2367, 2022. RAUSEI-MILLS, Veronica et al. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. American journal of clinical pathology, v. 129, n. 4, p. 624-629, 2008. REICHENHEIM, M. E. et al. Violência e lesões no Brasil: o efeito, os progressos realizados e os desafios à frente. Lancet, v. 377, p. 1962-75, 2011. REIS, Rogério et al. Description of lymphocyte and cytokine profiles in individuals with acute myeloid leukemia associated with FLT3-ITD and NPM1 mutation status. European Journal of Cancer Prevention, v. 34, n. 2, p. 115-123, 2025. REVILLE, Patrick K. et al. Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: revisiting the European LeukemiaNet adverse risk classification. American journal of hematology, v. 97, n. 3, p. 329-337, 2022. ROBBINS, Stanley; COTRAN, Ramzi S. Patologia bases patológicas das doenças. In: Patologia Bases patológicas das Doenças. 2016. ROLLINS-RAVAL, Marian et al. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Applied Immunohistochemistry & Molecular Morphology, v. 21, n. 3, p. 212-217, 2013. ROSNET, O.; BIRNBAUM, D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Critical reviews in oncogenesis, v. 4, n. 6, p. 595-613, 1993. SARIANI, Omid Karimdadi et al. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. Cytokine, v. 142, p. 155508, 2021. SCHNITTGER, S. et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia, v. 25, n. 8, p. 1297-1304, 2011. SHARVIT, Gal et al. Acute myeloid leukemia patients requiring two cycles of intensive induction for attainment of remission experience inferior survival compared with patients requiring a single course of induction chemotherapy. Clinical Lymphoma Myeloma and Leukemia, v. 22, n. 2, p. e116-e123, 2022. SHIMONY, Shai; STAHL, Maximilian; STONE, Richard M. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, v. 98, n. 3, p. 502-526, 2023. STONE, Michael et al. Phenotypic clues that predict underlying cytogenetic/genetic abnormalities in myeloid malignancies: A contemporary review. Cytopathology, v. 34, n. 6, p. 530-541, 2023. STONE, Richard M. et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. New England Journal of Medicine, v. 377, n. 5, p. 454-464, 2017. STILLWELL, Ross; BIERER, Barbara E. T cell signal transfuction and the role of CD7 in costimulation. Immunologic research, v. 24, p. 31-52, 2001. SU, Long et al. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology, v. 19, n. 6, p. 324-328, 2014. SUN, Jie et al. Acute myeloid leukemia with cup-like blasts and FLT3-ITD and NPM1 mutations mimics features of acute promyelocytic leukemia: a case of durable remission after sorafenib and low-dose cytarabine. Anti-Cancer Drugs, v. 33, n. 1, p. e813-e817, 2022. SIDNEY, Laura E. et al. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem cells, v. 32, n. 6, p. 1380-1389, 2014. TAKENOKUCHI, Mariko et al. FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia. Hematology Reports, v. 4, n. 4, p. e22, 2012. TEBBI, Cameron K. Etiology of acute leukemia: A review. Cancers, v. 13, n. 9, p. 2256, 2021. TETTAMANTI, Sarah et al. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia, v. 36, n. 1, p. 13-22, 2022. THIEDE, Christian et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, v. 107, n. 10, p. 4011-4020, 2006. WEI, Hui et al. Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian population. Journal of hematology & oncology, v. 11, p. 1-4, 2018. WIERNIK, Peter H. et al. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. British journal of haematology, v. 194, n. 2, p. 309-318, 2021. XU, Shuangnian et al. Prognostic value of CD11b expression level for acute myeloid leukemia patients: a meta-analysis. PLoS One, v. 10, n. 8, p. e0135981, 2015. ZHANG, Qianying et al. Neutrophil-to-lymphocyte ratio correlates with prognosis and response to chemotherapy in patients with non-M3 de novo acute myeloid leukemia. Translational cancer research, v. 10, n. 2, p. 1013, 2021. ZHAO, Jennifer C. et al. A review of FLT3 inhibitors in acute myeloid leukemia. Blood reviews, v. 52, p. 100905, 2022. ZHOU, Yeming et al. Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. Biomarker Research, v. 12, n. 1, p. 101, 2024. ZHOU, Yi et al. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1. Cytometry Part B: Clinical Cytometry, v. 96, n. 1, p. 67-72, 2019.pt_BR
dc.type.degreeMestrado Acadêmicopt_BR
Aparece nas coleções:Dissertação (PPGIM)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Muller_Dissertação_Mestrado_PPGIM.pdf2,94 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.